Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Western Digital Corp (WDC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Western Digital Corp — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Western Digital Corp trades at $535.49 (market cap $183.41B). The key difference: Western Digital Corp is far larger — about 40.8× ACADIA Pharmaceuticals Inc.'s market cap, and Western Digital Corp pays a 0.11% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WDC | |
|---|---|---|
Market Cap | $4.49B | $183.41B |
Sector | Health | Technology |
52-Week High | $28.06 | $746.23 |
52-Week Low | $20.06 | $64.02 |
Enterprise Value | $3.69B | $181.75B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Western Digital (WDC) trades at $532.1, down 1.28% amid a sector-wide memory stock sell-off. The stock shows strong fundamentals with three consecutive quarterly earnings beats and a net income margin of 55.07% in 2025. Analyst consensus is strongly bullish with a $607.46 price target, though technical indicators signal near-term bearish pressure with support at $523.
Outlook remains positive driven by AI and data center demand, but volatility from memory pricing cycles and competitive pressures pose risks. Upside depends on continued execution and sector momentum, with the current dip potentially offering entry for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
